来自MSN6 小时
Ataciguat's Headway in Aortic Stenosis; Baby Pacemakers; AI-ECG Tool for the ED?
The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...
TCTMD5 天
Aortic Stenosis Slowed by SGLT2 Inhibitors in Observational Study
If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.
New drug shows promise in reducing aortic valve surgeries
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.
Emerging technologies in cardiac interventional care
Discover how recent advancements in cardiovascular medicine, including TAVI and TEER, are revolutionizing heart disease ...
Science Daily1 天
New drug may reduce need for aortic valve surgeries by slowing disease progression
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...
News Medical on MSN1 天
New drug ataciguat shows promise for managing aortic valve stenosis
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.
Experts publish consensus on alternative access for transaortic valve replacement
The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides ...
Daily5 天
SGLT2 Inhibitors exhibit Potential for Slowing Aortic Stenosis Progression: Study
Researchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis ...
The American Journal of Managed Care6 天
Cardiovascular Magnetic Resonance Highlights Sex-Specific Characteristics in Aortic Stenosis
This multicenter study sheds more light on sex-based differences in aortic stenosis (AS) and argues the benefits of using cardiovascular magnetic resonance (CMR) to assess sex-based risks in AS.